Brokerage firm Citigroup Downgrades its rating on Zoetis Inc(NYSE:ZTS). In a research note issued to the investors, the brokerage major Raises the price-target to $50.00 per share. The shares have been rated Neutral. Previously, the analysts had a Buy rating on the shares. The rating by Citigroup was issued on Jun 10, 2016.
In a different note, Stifel Nicolaus said it Initiates Coverage on Zoetis Inc, according to a research note issued on Jun 1, 2016. The shares have been rated ‘Buy’ by the firm. On May 6, 2016, Goldman Sachs said it Downgrades its rating on Zoetis Inc. In the research note, the firm Raises the price-target to $46.00 per share. The shares have been rated ‘Sell’ by the firm. On Mar 15, 2016, Jefferies said it Maintains its rating on Zoetis Inc. In the research note, the firm Raises the price-target to $50.00 per share. The shares have been rated ‘Buy’ by the firm.
Zoetis Inc (ZTS) made into the market gainers list on Wednesdays trading session with the shares advancing 0.06% or 0.03 points. Due to strong positive momentum, the stock ended at $47.22, which is also near the day’s high of $47.71. The stock began the session at $47.19 and the volume stood at 35,17,855 shares. The 52-week high of the shares is $55.38 and the 52 week low is $37.73. The company has a current market capitalization of $23,431 M and it has 49,62,02,370 shares in outstanding.
Zoetis Inc has also declared a cash dividend of $0.0950 on May 12, 2016. The shares will quote ex-dividend on Jun 28, 2016 and the record date has been fixed on Jun 30, 2016. The dividend payable date has been fixed on Aug 30, 2016.
Zoetis Inc(ZTS) last announced its earnings results on May 4, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $1.16B. Analysts had an estimated revenue of $1.10B. Earnings per share were $0.48. Analysts had estimated an EPS of $0.41.
Zoetis Inc. is engaged in the discovery development manufacture and commercialization of animal health medicines and vaccines with a focus on both livestock and companion animals. The Company markets products across four regions: the United States Europe/Africa/Middle East Canada/Latin America and Asia/Pacific; eight species: the livestock species of cattle swine poultry sheep and fish and the companion animal species of dogs cats and horses and five product categories: anti-infectives vaccines parasiticides medicated feed additives and other pharmaceutical products. In addition its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.